Compare · NVO vs ZYBT
NVO vs ZYBT
Side-by-side comparison of Novo Nordisk A/S (NVO) and Zhengye Biotechnology Holding Limited (ZYBT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZYBT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $197.31B, about 2651.8x ZYBT ($74.4M).
- Over the past year, NVO is down 18.0% and ZYBT is down 84.4% - NVO leads by 66.3 points.
- NVO has hit the wire 6 times in the past 4 weeks while ZYBT has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for ZYBT).
- Company
- Novo Nordisk A/S
- Zhengye Biotechnology Holding Limited
- Price
- $44.57-1.33%
- $1.61-1.83%
- Market cap
- $197.31B
- $74.4M
- 1M return
- -6.62%
- -11.05%
- 1Y return
- -18.02%
- -84.37%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest ZYBT
- SEC Form 6-K filed by Zhengye Biotechnology Holding Limited
- Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement
- SEC Form 6-K filed by Zhengye Biotechnology Holding Limited
- Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity
- New insider Han Zhenfa claimed ownership of 42,963,748 units of Ordinary shares (SEC Form 3)
- SEC Form 3 filed by new insider Cheng Yuhong (Nmn)
- SEC Form 3 filed by new insider Song Songlin
- SEC Form 3 filed by new insider Wang Ping (Nmn)
- SEC Form 3 filed by new insider Jiang Ping (Piji)
- SEC Form 6-K filed by Zhengye Biotechnology Holding Limited